Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Frequency and outcomes of brain metastases in patients with HER2‐mutant lung cancers

30 Aug 2019

Abstract excerpt

BACKGROUND: Mutations in human epidermal growth factor receptor 2 (HER2; also known as ERBB2) are found in approximately 2% of lung adenocarcinomas. The frequency and clinical course of brain metastases in this oncogenic subset are ill defined. METHODS: Baseline and subsequent development of brain metastases was evaluated in consecutive patients with HER2-mutant (n = 98), epidermal growth factor receptor...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Brain Metastases and Treatment
Share to Lung Cancer Research Studies
Share to Lung Cancer Treatments and Mutations

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31469421
DOI: 10.1002/cncr.32461

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Frequency and outcomes of brain metastases in patients with HER2‐mutant lung cancersPMID 31469421Read ↗

Miliary metastases are associated with epidermal growth factor receptor mutations in non-small cell lung cancer: a population-based study.Semantic proximity Read ↗

Real World Characteristics and Clinical Outcomes of HER2-Mutant Non-Small Cell Lung Cancer Patients Detected by Next-Generation Sequencing.Semantic proximity Read ↗

The number of brain metastases predicts the survival of non-small cell lung cancer patients with EGFR mutation status.Semantic proximity Read ↗

Treatment outcomes and prognostic factors in patients with driver mutant non-small cell lung cancer and de novo brain metastasesSemantic proximity Read ↗

Role of Epidermal Growth Factor Receptor (EGFR) Inhibitors and Radiation in the Management of Brain Metastases from EGFR Mutant Lung Cancers.Semantic proximity Read ↗

EGFR mutation and brain metastasis in pulmonary adenocarcinomas.Semantic proximity Read ↗

Sequencing brain metastases and opportunities for targeted therapies.Semantic proximity Read ↗

EGFR mutated non-small cell lung cancer patients: more prone to development of bone and brain metastases?Semantic proximity Read ↗

Comparison of Prognosis Between Epidermal Growth Factor Mutation Positive and Negative Groups in Lung Adenocarcinoma Patients with Brain MetastasesSemantic proximity Read ↗

A retrospective analysis in patients with EGFR-mutant lung adenocarcinoma: is EGFR mutation associated with a higher incidence of brain metastasis?Semantic proximity Read ↗

EGFR mutation status on brain metastases from non-small cell lung cancer.Semantic proximity Read ↗

Mutational profiles of primary pulmonary adenocarcinoma and paired brain metastases disclose the importance of KRAS mutations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.